These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 16224383

  • 21. Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia.
    Silver RT.
    Leukemia; 2005 Jan; 19(1):39-43. PubMed ID: 15510207
    [Abstract] [Full Text] [Related]

  • 22. Hydroxyurea induced skin ulceration in myeloproliferative disorders.
    McLintock C, Ockelford PA.
    Aust N Z J Med; 2000 Jun; 30(3):373-6. PubMed ID: 10914756
    [No Abstract] [Full Text] [Related]

  • 23. Chronic myeloid leukaemia with marked thrombocytosis in a patient with thalassaemia major: complete haematological remission under the combination of hydroxyurea and anagrelide.
    Voskaridou E, Terpos E, Komninaka V, Eftyhiadis E, Mantzourani M, Loukopoulos D.
    Br J Haematol; 2002 Jan; 116(1):155-7. PubMed ID: 11841409
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Leg ulceration with associated thrombocytosis: healing of ulceration associated with treatment of the raised platelet count.
    Wirth K, Schoepf E, Mertelsmann R, Lindemann A.
    Br J Dermatol; 1998 Mar; 138(3):533-5. PubMed ID: 9580816
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Anagrelide for control of thrombocytosis due to myeloproliferative disorders.
    Harrison CN.
    Future Oncol; 2005 Oct; 1(5):609-18. PubMed ID: 16556037
    [Abstract] [Full Text] [Related]

  • 31. [Essential thrombocytemia and other myeloproliferations with thrombocytemia in the data of the register of patients treated with Thromboreductin till the end of 2006].
    Penka M, Schwarz J, Pavlík T, Pytlík R, Doubek M, Dulícek P, Pospísilová D, Kissová J, Hlusí A, Schützová M, Cerná O, Brychtová Y, Szotkowski T, Volková Z, Seghetová J, Vozobulová V, Hadacová I, Hochová I, Voglová J, Lhotanová T, Bubeník B, Zapletal O, Vránová M, Micaníková M, Dusek L.
    Vnitr Lek; 2007 Jun; 53(6):653-61. PubMed ID: 17702125
    [Abstract] [Full Text] [Related]

  • 32. Bilateral retinal vascular occlusive disease in essential thrombocythemia.
    Liu M, Lee AG, Rice L, Lambert HM.
    Retina; 1999 Jun; 19(6):563-4. PubMed ID: 10606460
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Essential thrombocythaemia treatment options: addressing patient-specific needs.
    Birgegård G.
    Eur J Haematol Suppl; 2007 Oct; (68):27-31. PubMed ID: 17727563
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Leg ulcers in patients with myeloproliferative disorders: disease- or treatment-related?
    Bader U, Banyai M, Böni R, Burg G, Hafner J.
    Dermatology; 2000 Oct; 200(1):45-8. PubMed ID: 10681614
    [Abstract] [Full Text] [Related]

  • 37. Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. an immunohistochemical and morphometric study of sequential trephine biopsies.
    Thiele J, Kvasnicka HM, Fuchs N, Brunnbauer K, Volkwein N, Schmitt-Graeff A.
    Haematologica; 2003 Oct; 88(10):1130-8. PubMed ID: 14555309
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Wither the platelet?
    Adamson JW.
    N Engl J Med; 1988 May 19; 318(20):1331-2. PubMed ID: 3362189
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.